Table 1.

The FDA (2017) Deutetrabenazine Dosage and Administration.

Disorder
Maximum dose of deutetrabenazine

Standard recommendation
Recommendation for CYP2D6 poor metabolizers

Chorea association with Huntington disease
48 mg
(24 mg twice daily)
36 mg per day
(18 mg twice daily)

Tardive dyskinesia
48 mg
(24 mg twice daily)
36 mg per day
(18 mg twice daily)

Please see Therapeutic Recommendations based on Genotype for more information from the FDA.
This FDA table is adapted from (1).

From: Deutetrabenazine Therapy and CYP2D6 Genotype

Cover of Medical Genetics Summaries
Medical Genetics Summaries [Internet].
Pratt VM, Scott SA, Pirmohamed M, et al., editors.
Copyright Notice

All Medical Genetics Summaries content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 International (CC BY 4.0) license which permits copying, distribution, and adaptation of the work, provided the original work is properly cited and any changes from the original work are properly indicated. Any altered, transformed, or adapted form of the work may only be distributed under the same or similar license to this one.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.